Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2006-000419-90-HU
EUCTR2006-000419-90-HU
Active, not recruiting
Not Applicable

A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis

TAP Pharmaceutical Products Inc.0 sites450 target enrollmentMay 11, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsErosive esophagitis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Erosive esophagitis
Sponsor
TAP Pharmaceutical Products Inc.
Enrollment
450
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 11, 2006
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Prior to any study\-specific procedures being performed, the subject voluntarily signs an Informed consent Form (ICF) and any privacy statement/authorization form required by the region in which the subject is participating, after having its contents fully explained and all questions answered. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) must approve the ICFs.
  • •2\. Subjects must have successfully completed the Phase 3 Study T EE04 084 or T EE04 085; and have endoscopically proven healed EE. .
  • •3\. All female subjects must agree to continued use of a double barrier method of birth control. Oral, injectable or patch contraceptives may be used as one method if the subject has been taking them for greater than three months duration at the Screening Visit. Subjects who have had a bilateral tubal ligation, hysterectomy or are post\-menopausal (the absence of menses for 1\-2 years with a Follicle\-Stimulating Hormone \[FSH] level \>40 IU/L or absence of menses for \>2 years) are not required to use birth control.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •1\. Any condition that may require surgery during the course of the study.
  • •2\. Use of prescription or non\-prescription proton pump inhibitors (PPIs), histamine (H2\) receptor antagonists or sucralfate throughout the study.
  • •3\. Chronic use (\>12 doses per month) of non\-steroidal anti\-inflammatory drugs (NSAIDs) including COX 2 NSAIDs throughout the study, however, low dose aspirin up to 325 mg per day is allowed.
  • •4\. Use of antacids \[except for study supplied Gelusil (U.S. sites) or a similar equivalent approved antacid (ex U.S. sites)] throughout the study.
  • •5\. Subjects using drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose throughout the study.
  • •6\. Use of misoprostil or prokinetics throughout the study.
  • •7\. Need for continuous anticoagulant therapy.
  • •8\. Evidence of uncontrolled systemic disease.
  • •9\. Subject who, in the opinion of the investigator, is unable to comply with the requirements of the study or is unsuitable for any reason.
  • •10\. Subjects who have participated in either maintenance study (T\-EE04\-086 or T EE04 087\).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis
EUCTR2006-000419-90-LVTAP Pharmaceutical Products Inc.450
Active, not recruiting
Phase 1
A study to learn about the safety and efficacy of CTX001 (the study drug product) to treat beta-thalassemia in pediatric subjectsTransfusion-Dependent ß ThalassemiaMedDRA version: 20.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
EUCTR2021-002172-39-DEVertex Pharmaceuticals Incorporated15
Active, not recruiting
Phase 1
A study to learn about the safety and efficacy of CTX001 (the study drug product) to treat severe sickle cell disease in pediatric subjectsSevere Sickle Cell Disease (SCD)MedDRA version: 21.0Level: PTClassification code 10040641Term: Sickle cell anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
EUCTR2021-002173-26-DEVertex Pharmaceuticals Incorporated15
Active, not recruiting
Not Applicable
A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive EsophagitisErosive esophagitis
EUCTR2006-000419-90-EETAP Pharmaceutical Products Inc.450
Active, not recruiting
Not Applicable
A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive EsophagitisErosive esophagitis
EUCTR2006-000419-90-CZTAP Pharmaceutical Products Inc.450